Drug intelligence / Profile preview

HL 10

Development stage: Discontinued
Lead developer: LEO Pharma
Modality: Recombinant Proteins and Enzymes
Administration: Instillation

Overview

HL 10 is a freeze-dried drug developed by LEO Pharma. It is an exogenous natural porcine surfactant that functions as a cell membrane permeability enhancer. It was investigated in a Phase III clinical trial for the treatment of Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS). The trial indicated that HL 10 did not improve patient outcomes and showed a trend towards increased mortality and adverse effects, leading to its discontinuation.

Other names: Freeze dried HL 10exogenous natural porcine surfactant HL 10

Targets

ACE (Angiotensin Converting Enzyme)

Beyond the preview

Go deeper on HL 10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HL 10.

Explore the full profile